Correlation study for expression of peripheral blood Th17/Treg cell axis in HSPN patients

Phase 1

Recruiting

• Conditions: Henoch-Sch?nlein purpura nephritis(HSPN)

• Registration Number: ITMCTR1900002525
• Lead Sponsor: Hubei University of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.Inclusion criteria of study group(HSPN subjects) :
1) Aged 18-60 years;
2) In accordance with diagnostic criteria of HSPN in the Clinical Guidelines-Nephrology Section which was edited by the Chinese medical association in 2011;
3) eGFR >=60 (mL/min / 1.73 m2; the MDRD formula);
4) 24-h UTP <=3.0 g;
5) Willing to provide informed consent and complete the process required by the study.

2.Inclusion criteria of control group (healthy subjects):
1) Aged 18-60 years;
2) Routine items such as blood, urine, feces, liver and kidney functions, and blood lipids are within the normal range in medical examination reports;
3) To provide informed consent.

Exclusion Criteria

1.Exclusion criteria of study group(HSPN subjects) :
1) Women during pregnancy or lactation;
2) Participating in interventional clinical trials
3) Patients who have been treated with glucocorticoids and immunosuppressants for the past 3 months or are being treated due to HSPN;
4) I or II type diabetes;
5) NYHA Class III or IV heart failure;
6) Viral hepatitis or cirrhosis;
7) HIV infection or AIDS;
8) Malignant tumors;
9) Have been receiving dialysis for more than 1month, and/or organ or bone marrow transplantation;
10) Have been diagnosed as polycystic kidney and other hereditary kidney diseases.

2.Exclusion criteria of control group(healthy subjects) :
1) Persons who have a history of chronic diseases such as hypertension, diabetes, coronary heart disease, hyperuricemia or hyperlipidemia;
2) Persons who have a history of genetic diseases;
3) Patients with immunological and allergic diseases;
4) Patients with malignant tumors.

Study & Design

• Study Type: Basic Science
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ROR?t, Foxp3;IL-17, IL-10;Th17, Treg;